What is New Managing Lipids?

Recent Developments in the Field of Lipid Management

Guest: Stephen L. Kopecky, M.D. (@DrSteveKopecky)

Host: Thomas G. Allison, Ph.D., M.P.H. (@DrTAllison)

Statins and lifestyle changes are still the first line choices for the management of low-density lipoprotein (LDL) cholesterol to reduce the risk of heart disease. Recent developments in the field of lipid management, however, provide promising treatment options for patients who are statin intolerant or simply not achieving their LDL goals, or have elevated levels of triglycerides or lipoprotein(a), also called LP(a).

Joining us today to discuss recent developments in the field of lipid management is Stephen L. Kopecky, M.D., a preventive cardiologist here at Mayo Clinic in Rochester, Minnesota.

Specific topics discussed:

The end of the statin era?

New treatment options for patients who are statin intolerant

Triglycerides: fibrates and statins — and fish oil

LP(a) as a risk marker in patients with atherosclerotic cardiovascular disease or familial hyperlipidemia

Use of proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) inhibitors

Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV.

No CME credit offered for this episode.

Podcast transcript can be found here.